Title: Glucagon-like peptide-1 receptor activation and mental health: a drug-target Mendelian

randomization study

Short title: GLP-1R and mental health

Authors:

Guoyi Yang, PhD[a,b*], Stephen Burgess, PhD[c,d], C Mary Schooling, PhD[a,e]

[a] School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong,

Hong Kong, China

[b] Department of Medicine, Perelman School of Medicine, University of Pennsylvania,

Philadelphia, USA

[c] MRC Biostatistics Unit, University of Cambridge, Cambridge, UK

[d] British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health

and Primary Care, University of Cambridge, Cambridge, UK

[e] Graduate School of Public Health and Health Policy, City University of New York, New

York, USA

[*]**Corresponding author: Guoyi Yang, PhD**

Postal address: 1/F, Patrick Manson Building, 7 Sassoon Road, Pokfulam, Hong Kong

Email address: yanggy@connect.hku.hk

Telephone: +852 98147624

ORCID: 0000-0002-4387-386X

Word count: 3923

The number of tables: 0

The number of figures: 4

The number of eTables: 13

The number of eFigures: 4

Abstract

Background: Concerns have been raised about the psychiatric safety of glucagon-like peptide-1 receptor (GLP-1R) agonists, but trial evidence suggests that they ameliorate depressive symptoms. We aimed to assess the associations of GLP-1R activation with mental health well-being and the risk of mental health disorders and substance use disorders.

Methods: We performed drug-target Mendelian randomization and colocalization analyses using the largest relevant genome-wide association studies and replicated in FinnGen.

Results: After correcting for multiple comparisons, genetically predicted lower body mass index (BMI) via GLP-1R activation was associated with a better well-being spectrum (0.06 standard deviation [95% confidence interval 0.03-0.08]) and lower risk of depression (odds ratio 0.83 [0.74-0.94]) and bipolar disorder (odds ratio 0.61 [0.47-0.79]) per 1-kg/m^2 decrease in BMI. There was also suggestive evidence that genetically predicted lower BMI via GLP-1R activation was associated with lower risk of post-partum depression, attention deficit hyperactivity disorder, and substance use disorders, and that genetically predicted lower glycated hemoglobin (HbA1c) via GLP-1R activation was associated with higher risk of anorexia nervosa but lower risk of Tourette syndrome. These associations were stronger than the associations for genetically predicted lower BMI and lower HbA1c based on genome-wide variants. The posterior probabilities of a shared causal variant affecting both BMI and the outcome at *GLP1R* were 59.3% for the well-being spectrum, 3.8% for depression, and 45.9% for bipolar disorder.

Conclusions: GLP-1R activation was associated with better mental health well-being and

lower risk of depression and bipolar disorder beyond that expected from the reduction in BMI

and HbA1c.

(Word count: 250)

Keywords: bipolar disorder, depression, glucagon-like peptide-1 receptor, Mendelian

randomization, mental health

Key messages

• This drug-target Mendelian randomization study showed that genetically predicted

glucagon-like peptide-1 receptor (GLP-1R) activation was associated with better mental

health well-being and lower risk of depression and bipolar disorder.

• The associations of genetically predicted GLP-1R activation with favorable mental health

outcomes were beyond that expected from the reduction in body mass index (BMI) and

glycated hemoglobin (HbA1c).

• This genetic evidence suggests repurposing opportunities of GLP-1R agonists for

improving mental health.

Introduction

Glucagon-like peptide-1 receptor (GLP-1R) agonists reduce body weight and blood glucose.[1] Randomized controlled trials (RCTs) have shown cardiovascular and mortality benefits of GLP-1R agonists.[2,3] GLP-1R agonists act on the hindbrain, the hypothalamus, and vagal afferents to suppress food intake and reduce body weight.[4-6] Anti-obesity drugs affecting central nervous systems could have psychiatric effects. For example, the combination of phentermine and topiramate increases depression and anxiety.[7] Rimonabant was withdrawn from the market due to serious psychiatric adverse events.[8] In contrast, the combination of naltrexone and bupropion improves depression,[9] smoking cessation,[10,11] and methamphetamine use disorder.[12]

Following reports of suicidal ideation and self-injury in people using GLP-1R agonists,[13] the European Medicines Agency and the US Food and Drug Administration have been monitoring the psychiatric safety of GLP-1R agonists. To date, the available evidence does not suggest a causal association of GLP-1R agonist use with suicidal thoughts and actions.[14,15] RCTs have suggested that GLP-1R agonists moderately reduce depressive symptoms in people who are overweight or obese[16] and in people with type 2 diabetes.[17] Animal,[18,19] observational,[20,21] and genetic studies[22] suggest potential benefits of GLP-1R agonists in alcohol use disorder; however, RCTs have yielded contradictory evidence showing benefits or null effects.[23,24] Early-stage trials are on-going to investigate the efficacy of GLP-1R agonists in individuals with mental illnesses[25] and substance use disorders.[26] A better understanding of the

association of GLP-1R activation, the intended target of GLP-1R agonists, with mental health

has implications for informing their psychiatric safety and potential repurposing

opportunities.

To address this gap, we used Mendelian randomization (MR), an instrumental variable

analysis with genetic instruments, to obtain less confounded estimates than conventional

observational studies.[27] Previous MR studies suggested no association of GLP-1R activation

with suicide risk,[28,29] consistent with an RCT.[16] We used MR to assess the associations of

GLP-1R activation with mental health outcomes including the well-being spectrum, mental

health disorders, and substance use disorders. We further investigated whether any

associations were explained by lowering body mass index (BMI) or lowering glycated

hemoglobin (HbA1c).

Methods

Study design

MR relies on the instrumental variable assumptions of relevance (the genetic instruments

should be related to the exposure), independence (no common cause of the genetic

instruments and the outcome exists), and exclusion restriction (the genetic instruments should

be independent of the outcome given the exposure).[30] This MR study took advantage of the

largest relevant publicly available genome-wide association studies (GWASs) (eTable 1).

First, we assessed the associations of GLP-1R activation predicted by *GLP1R* variants with

mental health outcomes including the well-being spectrum, mental health disorders, and

substance use disorders. We compared these associations with the associations for lower BMI

and lower HbA1c predicted by genome-wide variants. Second, we performed colocalization

analyses to examine whether any associations found for GLP-1R activation were driven by a

shared causal variant affecting both BMI or HbA1c and the outcome at the *GLP1R* gene.[31]

Where possible, we conducted sex-specific analyses, because women are more likely to have

depression than men,[32] but boys are more likely to develop neurodevelopmental disorders

than girls.[33]

Genetic instruments

We selected genetic instruments for GLP-1R activation based on their associations with

downstream traits related to drug target effects (BMI and HbA1c), because this approach

reduces the risk of the variant-outcome association being lost or confounded by pleiotropic

effects.[34] We obtained genetic associations with BMI ($N = 806,834$) from a meta-analysis of

the UK Biobank and GIANT[35] and with HbA1c ($N = 344,182$) from a GWAS of the UK

Biobank.[36] We considered these two sets of instruments separately, because they might

represent distinct mechanisms.[37] For primary analyses, we extracted variants in or near (+-

1Mb) the *GLP1R* gene that were uncorrelated ($r^2<0.001$) and genome-wide significantly (*p*

value $<5\times10^{-8}$) associated with BMI to mimic BMI-related mechanisms. We used the same

approach based on their associations with HbA1c to select genetic variants mimicking

HbA1c-related mechanisms. For sensitivity analyses, we used a less stringent significance

threshold for instrument selection (p value $< 1\times10^{-5}$). For comparison, we also extracted

genetic instruments for BMI and HbA1c from across the genome (genome-wide variants) that

were uncorrelated ($r^2 <0.001$) and genome-wide significantly (p value $<5\times10^{-8}$) associated

with BMI and HbA1c, respectively.

We used coronary artery disease (CAD), the most common cardiovascular disease, and all-

cause mortality as positive control outcomes, because RCTs have shown that GLP-1R

agonists reduce cardiovascular events and death.[2,3] We obtained genetic associations with

CAD (181,522 cases/984,168 controls) from a meta-analysis of the CARDIoGRAMplusC4D

consortium and the UK Biobank.[40] We obtained genetic associations with parental mortality

(609,139 cases/403,101 controls), determined by parental attained age and their alive/dead

status, from a meta-analysis of the UK Biobank and LifeGen as a measure of all-cause

mortality,[41] because it has greater power than participant's mortality. We used skin color ($N =$

356,530) obtained from the UK Biobank[36] as a negative control outcome. We also queried the

genetic instruments for GLP-1R activation in the IEU OpenGWAS database to assess possible

pleiotropic effects (p value $<1\times10^{-5}$).

Genetic associations with mental health outcomes

We obtained sex-combined and sex-specific genetic associations with mental health outcomes

from the largest relevant publicly available GWASs.[36,42-56] Primary outcomes included the

well-being spectrum, mental health disorders (depression, bipolar disorder, post-traumatic

stress disorder (PTSD), schizophrenia, anorexia nervosa, attention deficit hyperactivity

disorder (ADHD), autism spectrum disorder, and Tourette's syndrome), and substance use

disorders. Secondary outcomes included four dimensions of mental health well-being (life

satisfaction, positive affect, neuroticism, and depressive symptoms) and subtypes of mental

health disorders (postpartum depression and bipolar disorder I and II) and substance use

disorders (cannabis use disorder and alcohol dependence). Secondary outcomes also included

the Alcohol Use Disorders Identification Test (AUDIT) total score, score for alcohol

consumption, and score for alcohol problems. We obtained genetic associations with relevant

outcomes from the FinnGen R12 for replication, where possible.[57] Genetic associations with

binary outcomes obtained using linear regression were transformed into odds ratio (OR) using

an established approximation.[58]

MR analysis

We used the F-statistic to assess instrument strength, approximated by the square of SNP-

exposure association divided by the square of its standard error.[59] An F-statistic larger than 10

suggests weak instrument bias is unlikely. We aligned SNPs on the same allele for exposure

and outcome, and used proxy SNPs ($r^2>0.8$), where possible, when SNPs were not available

in the outcome GWAS. We calculated Wald estimates by dividing genetic association with

outcome by genetic association with exposure. We obtained MR estimates by meta-analyzing

Wald estimates using inverse variance weighting (IVW) with fixed effects for three SNPs or

fewer and random effects for four SNPs or more.[60] To assess the robustness of IVW estimates,

we conducted sensitivity analyses using the weighted median,[61] MR Egger,[62] and MR using

the robust adjusted profile score (MR-RAPS).[63] We used the Cochran's Q statistic[64] to test

heterogeneity in Wald estimates and the MR Egger intercept[62] to assess directional pleiotropy.

We used the Steiger filtering to identify the SNPs explaining more variance in the outcome

than in the exposure (p value < 0.05).[65] We conducted sensitivity analyses excluding the SNPs

identified to assess whether MR estimates were affected by reverse causation. We used a

Bonferroni-corrected significance level of $\alpha=0.05/10=0.005$ given ten primary outcomes. We

considered nominally significant associations (p value <0.05) that did not reach Bonferroni-

corrected significance as suggestive evidence. We tested differences by sex using a two-sided

z-test.[66]

Colocalization

We performed pairwise colocalization analyses in a Bayesian framework to assess whether

any associations found for GLP-1R activation were driven by a shared causal variant affecting

both BMI or HbA1c and the outcome or were confounded by linkage disequilibrium.[31] We

included variants (minor allele frequency >0.1%) in or near (+- 1Mb) the *GLP1R* gene. We set

the prior probabilities as recommended, that is 10^{-4} for a variant associated with BMI or

HbA1c, 10^{-4} for a variant associated with the outcome, and 10^{-5} for a variant associated with

both traits.[31] We assessed the posterior probability of several hypotheses, including H_0 (no

association with either trait), H_1, (association with BMI or HbA1c only); H_2, (association with

the outcome only); H_3, (associations of two independent variants and one for each trait); H_4

(associations of one shared variant with both traits).[31] A posterior probability of H_4 larger than

0.80 suggests colocalization.[31] The power to detect colocalization is low when the variants are

not strongly associated with the outcome, so we also calculated the posterior probability of

colocalization (H_4) conditional on the presence of a variant associated with the outcome as

$H_4/(H_2 + H_3 + H_4)$.[67] We reported the posterior probabilities of H_0-H_4 and conditional H_4 and

the variant with the largest posterior probability of being the shared causal variant.

We also used the Hypothesis Prioritisation for multi-trait Colocalization (HyPrColoc)[68] to

assess colocalization across multiple traits identified for GLP-1R activation. We set the prior

probability for a variant associated with at least one trait as 10^{-4} and the conditional prior

probability for a variant associated with an additional trait given that the variant is associated

with at least one other trait as 0.02.[68] We reported clusters of putatively colocalized traits and

the posterior probability of colocalization.

All statistical analyses were conducted using R version 4.2.1 and the packages "ieugwasr",

"TwoSampleMR", "MendelianRandomization", "mr.raps, "metafor", "coloc", and

"hyprcoloc".

Results

Genetic instruments

For primary analyses, we used two *GLP1R* SNPs (rs17757975 and rs4714290) genome-wide

significantly associated with BMI to predict the impact of GLP-1R activation as indicated by

lower BMI; we used one *GLP1R* SNP (rs10305518) genome-wide significantly associated

with HbA1c to predict the impact of GLP-1R activation as indicated by lower HbA1c (eTable

2). For sensitivity analyses, we used three *GLP1R* SNPs for BMI and two *GLP1R* SNPs for

HbA1c based on a more lenient significance threshold (p value $< 1 \times 10^{-5}$) (eTable 2). Beyond

BMI and HbA1c, some of these genetic instruments were associated with body composition,

body impedance, basal metabolic rate, atrial fibrillation, age at menarche, gastroesophageal

reflux disease, or area of the left inferior temporal region (p value $< 1 \times 10^{-5}$) (eTable 3). The

GLP1R SNPs for BMI were not associated with HbA1c and vice versa (eTable 4), which

substantiated that the two sets of genetic instruments represent distinct mechanisms of GLP-

1R activation.[37] For comparison, we also extracted 516 (overall), 303 (women), and 256

(men) SNPs for BMI and 318 (overall), 200 (women), 174 (men) SNPs for HbA1c from

across the genome (eTable 5). The F-statistics of the primary instruments were all >10

(eTables 2 and 5).

In positive control analyses, genetically predicted lower BMI and lower HbA1c via GLP-1R

activation were associated with lower CAD risk and all-cause mortality, despite wide

confidence intervals (CIs) (eFigure 1). The point estimates for genetically predicted lower

BMI and lower HbA1c via GLP-1R activation were comparable to those for genetically

predicted lower BMI and lower HbA1c based on genome-wide variants (eFigure 1 and eTable

6). In negative control analyses, genetically predicted lower BMI and lower HbA1c via GLP-

1R activation were not associated with skin color (eTable 7).

Associations of GLP-1R activation with mental health well-being

Genetically predicted lower BMI via GLP-1R activation was associated with a better well-

being spectrum, including life satisfaction, positive affect, neuroticism, and depressive

symptoms (Figure 1). The associations with depressive symptoms were similar in women and

men (eFigure 2). These associations were stronger than the associations for genetically

predicted lower BMI using genome-wide variants (Figure 1). However, genetically predicted

lower HbA1c via GLP-1R activation had little association with mental health well-being

(Figure 1). The Cochran's Q statistics suggested heterogeneity; however, the MR Egger

intercept did not indicate directional pleiotropy and the weighted median, MR Egger, and

MR-RAPS gave consistent estimates (eTables 8-9). The Steiger filtering identified no SNP

that explained more variance in the outcome than in the exposure (eTable 8-9).

Associations of GLP-1R activation with the risk of mental health disorders

Genetically predicted lower BMI via GLP-1R activation was associated with lower risk of

depression, postpartum depression, bipolar disorder, bipolar disorder I and II, and ADHD

(Figure 2). The association with depression was possibly stronger in women (OR (95% CI)

0.75 (0.52 to 1.08)) than men (0.98 (0.65 to 1.47)), although the *p* value for sex difference

was 0.35 (eFigure 3). These associations were stronger than the associations for genetically

predicted lower BMI using genome-wide variants (Figure 2). Genetically predicted lower

HbA1c via GLP-1R activation was associated with higher risk of anorexia nervosa but lower

risk of Tourette syndrome, with stronger associations than the associations for genetically

predicted lower HbA1c using genome-wide variants (Figure 2). The MR Egger intercept

suggested some directional pleiotropy for genetically predicted lower BMI and lower HbA1c

using genome-wide variants (eTable 10). However, the results were similar when using

different MR methods and when excluding the SNPs explaining more variance in the outcome

than in the exposure identified by the Steiger filtering (eTable 10).

Associations of GLP-1R activation with the risk of substance use disorders

Genetically predicted lower BMI via GLP-1R activation was associated with lower risk of

substance use disorders and lower AUDIT score for alcohol problems, with stronger

associations than the associations for genetically predicted lower BMI using genome-wide

variants (Figure 3). However, genetically predicted lower HbA1c via GLP-1R activation had

little association with the risk of substance use disorders (Figure 3). The MR Egger intercept

suggested some directional pleiotropy for genetically predicted lower BMI and lower HbA1c

using genome-wide variants, but sensitivity analyses using different MR methods and

excluding the SNPs identified by the Steiger filtering gave similar interpretations (eTable 11).

Replication

In FinnGen, genetically predicted lower BMI via GLP-1R activation was associated with

lower risk of depression, bipolar disorder, PTSD, ADHD, substance abuse, and alcohol

dependence (eFigure 4). These associations were stronger than those for genetically predicted

lower BMI using genome-wide variants (eFigure 4). Genetically predicted lower HbA1c via

GLP-1R activation had little association with mental health outcomes except for depression

(eFigure 4). Nevertheless, this association was attenuated to null when using the two SNPs

extracted based on a more lenient significance threshold (eTable 12).

Colocalization

After correcting for multiple comparisons, genetically predicted lower BMI via GLP-1R

activation remained significantly associated with the well-being spectrum, life satisfaction,

positive affect, neuroticism, depressive symptoms, depression, bipolar disorder, and bipolar

disorder I (*p* values <0.005). Pairwise colocalization analyses were performed for BMI and

each significant outcome in or near the *GLP1R* gene. The posterior probabilities of

colocalization were <80% for all the significant outcomes (Figure 4). However, conditioning

on the presence of a variant associated with the outcome, the posterior probabilities of

colocalization were all >80% except for depression (Figure 4), suggesting that some lack of

colocalization was due to limited power. The posterior probabilities of two independent

variants associated with each trait were <15% for all the significant outcomes (eTable 13),

suggesting that confounding by linkage disequilibrium was unlikely. Across the *GLP1R* gene

region, rs4714290, rs847784 (a proxy for rs4714290, $r^2 = 0.89$), or rs17757975 had the largest

posterior probability of being the shared causal variant, which substantiated their validity as

genetic instruments.

Multi-trait colocalization analyses were performed across BMI and all the significant

outcomes in or near the *GLP1R* gene. We identified BMI, the well-being spectrum, life

satisfaction, positive affect, neuroticism, depressive symptoms as a cluster of putatively

colocalized traits with the posterior probability of colocalization 51.9%.

Discussion

Consistent with some RCTs,[16,17] this MR study suggests that GLP-1R activation is associated

with lower risk of depression. We build on the evidence base by showing that GLP-1R

activation is associated with a better well-being spectrum and lower risk of bipolar disorder.

We also provide suggestive evidence that GLP-1R activation is associated with lower risk of

postpartum depression, ADHD, Tourette syndrome, and substance use disorders but higher

risk of anorexia nervosa. These associations were stronger than those expected from the

reduction in BMI and HbA1c.

Our investigations suggest that GLP-1R activation is associated with a better well-being

spectrum and lower risk of depression and bipolar disorder. Consistently, RCTs have shown

that GLP-1R agonists moderately reduce depression symptoms in overweight people[16] and in

people with type 2 diabetes.[17] A small open-label trial showed that liraglutide, as an adjunct to

existing pharmacotherapy, improved cognitive function[69] and brain volumes[70] in people with

depression or bipolar disorder. GLP-1 has neuroprotective effects including enhanced

neurogenesis, improved barrier function, reduced neuroinflammation, and decreased oxidative

stress.[71] These effects might contribute to the psychiatric benefits of GLP-1R activation and

are consistent with RCTs showing that GLP-1R agonists improve neurodegenerative diseases,

such as Parkinson's disease.[72,73]

Interestingly, the associations of GLP-1R activation with mental health well-being,

depression, and bipolar disorder were evident when instrumenting on BMI but not on HbA1c,

suggesting the relevance of BMI-related mechanisms. A recent study showed that GLP-1R

agonists target the hindbrain dorsal vagal complex to decrease food intake and body weight.[4]

Actions on the hypothalamus and vagal afferents also contribute to the weight loss on GLP-

1R agonists.[5,6] GLP neurons in the dorsal vagal complex moderate stress responses and

stimulate hypothalamic-pituitary-adrenal (HPA) axis activity, which has been implicated in

the pathology of depression[74] and bipolar disorder.[75] Notably, the HPA axis is also related to

cognitive function,[74,75] consistent with an RCT showing that dulaglutide reduces cognitive

impairment in people with type 2 diabetes.[76] Additional studies are warranted to elucidate the

mechanisms underlying potential benefits of GLP-1R agonists for mental health.

We found that GLP-1R activation was possibly associated with lower risk of depression more

in women than men and was associated with lower risk of postpartum depression. We caution

that the power to detect sex differences may have been limited by small or unequal sample

sizes of sex-stratified GWAS. Women are about twice as likely as men to have depression

during their lifetime with the difference starting at puberty.[32] A meta-analysis of RCTs showed

that GLP-1R agonists decreased testosterone and increased sex hormone-binding globulin in

women with polycystic ovary syndrome,[77] but their effects on estrogen are less clear. Sex

hormones might contribute to GLP-1R activation improving depression in women, given their

potential roles in modulating serotonergic neurotransmission, cortisol, and oxytocin.[78]

GLP-1R activation was not associated with higher risk of neurodevelopmental disorders

including ADHD, autism spectrum disorder, and Tourette syndrome. Although RCTs have

showed the short-term (no more than 26 weeks) safety of GLP-1R agonists in children and

adolescents,[79] RCTs typically do not capture the long latency of neurodevelopmental

disorders. Our study adds to the evidence by showing little adverse effect of lifelong GLP-1R

activation on these disorders. However, GLP-1R activation was possibly associated with

higher risk of anorexia nervosa when instrumenting on HbA1c. GLP-1R activation increases

insulin secretion and sensitivity and lowers glucose.[80] A previous MR study suggested an

inverse association of fasting insulin with the risk of anorexia nervosa,[81] indicating a role of

insulin sensitivity.

We provide suggestive evidence that GLP-1R activation is associated with lower risk of

substance use disorders and lower AUDIT score for alcohol problems. Although the benefits

of GLP-1R activation on substance abuse and alcohol dependence were replicated in

FinnGen, this evidence should be treated with caution. A recent RCT showed that eight-week

treatment with semaglutide reduced alcohol consumption and craving in people with alcohol

use disorder.[24] In contrast, another RCT including people with alcohol use disorder showed

that 26 weeks of treatment with exenatide did not significantly reduce heavy drinking days,

although exenatide attenuated fMRI alcohol cue reactivity in brain areas for drug reward and

addiction.[23] Further evidence from RCTs is needed to determine the repurposing opportunities

of GLP-1R agonists for treating substance use disorders.

We presented the MR estimates of GLP-1R activation in effect sizes of BMI or HbA1c

reduction for interpretability. However, this scaling does not imply that weight loss or glucose

lowering is the sole mechanism of action for the psychiatric effects of GLP-1R activation.

Indeed, the associations of GLP-1R activation with mental health outcomes exceeded those

expected from lowering BMI and HbA1c. Correspondingly, RCTs have showed that

semaglutide reduces cardiovascular events and mortality more than expected from the

reduction in body weight,[16] and that GLP-1R agonists outperform other anti-diabetes drugs.[82]

Apart from reducing body weight and glucose, GLP-1R agonists also decrease blood pressure,

low-density lipoprotein cholesterol, and inflammation and enhance kidney function.[2,3] We

extend the evidence by suggesting that GLP-1R activation is associated with better mental

health beyond that expected from the reduction in BMI and HbA1c, which may also

contribute to the cardiovascular and mortality benefits of GLP-1R agonists.[83] A parsimonious

model explaining the multifaceted effects of GLP-1R agonists would be helpful. For example,

GLP-1R agonists activating 5' adenosine monophosphate-activated protein kinase

(AMPK)[84,85] can explain several aspects of their benefits, given the central role of AMPK in

metabolism across tissues including the brain.[86]

This is the first drug-target MR study comprehensively exploring the associations of GLP-1R

activation with mental health outcomes. The finding that GLP-1R activation is associated with

better mental health well-being and lower risk of bipolar disorder is novel. Our investigation

also has implications for the use of GLP-1R agonists in people with mental health disorders,

who usually have higher risk of obesity and type 2 diabetes but are undertreated. This study

has several limitations. First, MR relies on three rigorous assumptions, that is genetic

instruments should be related to the exposure, share no common cause with the outcome, and

be independent of the outcome given the exposure.[30] The F-statistics were >10, suggesting

minimal weak instrument bias. We validated the genetic instruments using CAD and all-cause

mortality as positive control outcomes. We used MR methods with different assumptions

about instrumental validity, which gave consistent estimates. Second, we selected genetic

instruments for GLP-1R activation based on their associations with BMI and HbA1c, but

additional underlying factors may explain their psychiatric effects. Instrumenting on BMI and

HbA1c could have masked some effects of GLP-1R activation. Third, the small number of

genetic instruments for GLP-1R activation, even when applying a more lenient significance

threshold for instrument selection, may have limited the detection of possible causal effects or

directional pleiotropy. Fourth, we obtained genetic associations with BMI from a meta-

analysis of the UK Biobank and GIANT and with HbA1c from the UK Biobank, which

overlaps with some outcome GWASs. Two-sample MR methods in a one-sample setting

perform well in terms of bias and precision in large biobanks, except for MR Egger which can

result in bias reflecting the direction and magnitude of confounding.[87] We replicated the

results using outcome GWASs from FinnGen, which has no overlap with the UK Biobank or

GIANT. Fifth, the power to detect colocalization was insufficient. However, the posterior

probabilities of two independent variants associated with each trait were <15% for all the

significant outcomes, suggesting that the associations found were unlikely driven by

confounding due to linkage disequilibrium. Sixth, MR can be open to selection bias from

selecting on genetic makeup and mental health disorders. Nevertheless, such selection should

bias towards a harmful effect of GLP-1R activation, which does not explain its associations

with lower risk of depression and bipolar disorder. Seventh, we obtained genetic associations

with mental health disorders from GWAS meta-analyses where outcome definitions may vary

across studies. Also, mental health disorders sometimes originate during childhood or

adolescence, but GLP-1R agonists are primarily used in adults. Our MR study assessed

lifelong effects of GLP-1R activation on mental health, which cannot directly inform the

short-term effects of GLP-1R agonists. The efficacy of GLP-1R agonists can also depend on

their pharmacological properties, the population treated, and the timing of treatment. RCTs

are warranted to determine the clinical relevance of these findings in the future.

Conclusions

421 This drug-target MR study provides genetic evidence that GLP-1R activation is associated

422 with better mental health well-being and lower risk of depression and bipolar disorder beyond

423 that expected from the reduction in BMI and HbA1c.

List of abbreviations

ADHD, attention deficit hyperactivity disorder

AMPK, 5' adenosine monophosphate-activated protein kinase

AUDIT, Alcohol Use Disorders Identification Test

BMI, body mass index

CAD, coronary artery disease

GLP-1R, glucagon-like peptide-1 receptor

GWAS, genome-wide association studies

HbA1c, glycated hemoglobin

HPA, hypothalamic-pituitary-adrenal

HyPrColoc, Hypothesis Prioritisation for multi-trait Colocalization

IVW, inverse variance weighting

MR, Mendelian randomization

OR, odds ratio

PTSD, post-traumatic stress disorder

RAPS, robust adjusted profile score

RCT, randomized controlled trials

Declarations

Ethics approval and consent to participate

All the analyses were conducted using publicly available summary statistics, which does not

require ethical approval. Participants of the original studies of publicly available summary

statistics provided informed consent.

Availability of data and materials

Summary statistics analyzed are available in the website

https://doi.org/10.5281/zenodo.1251813 for BMI, http://www.nealelab.is/uk-biobank/ for

HbA1c, https://www.cardiogramplusc4d.org/data-downloads/ for CAD,

https://www.ebi.ac.uk/gwas/publications/30642433 for parental mortality,

https://www.ebi.ac.uk/gwas/publications/30643256 for mental health well-being, and

https://pgc.unc.edu/for-researchers/download-results/ and

https://www.finngen.fi/en/access_results for mental health disorders and substance use

disorders.

Competing interests

The authors declared no conflict of interest.

Funding

SB is supported by the Wellcome Trust (225790/Z/22/Z) and the United Kingdom Research

and Innovation Medical Research Council (MC_UU_00002/7). The funders had no role in the

study design, analyses, or interpretation of results.

Author contributions

GY and CMS designed the study. GY undertook analyses with feedback from SB and CMS.

GY drafted the manuscript with critical feedback and revisions from SB and CMS. All authors

read and approved the final version of the manuscript. GY had full access to all the data in the

study and takes responsibility for the integrity of the data and the accuracy of the data

analysis.

Acknowledgements

475   The authors acknowledge Pulit SL, et al., the Neale lab, the CARDIoGRAMplusC4D

476   Consortium, Timmers PR, et al., Baselmans BML, et al., the Psychiatric Genomics

477   Consortium, and FinnGen for their publicly available summary data.

Artificial intelligence (AI)-assisted technologies

480   The authors declared that AI-assisted technologies were not used in this study.

References

1. Andersen A, Lund A, Knop FK, Vilsbøll T. Glucagon-like peptide 1 in health and disease. *Nature reviews Endocrinology*. Jul 2018;14(7):390-403. doi:10.1038/s41574-018-0016-2

2. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. *N Engl J Med*. Dec 14 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563

3. Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. *Lancet Diabetes Endocrinol*. Oct 2021;9(10):653-662. doi:10.1016/s2213-8587(21)00203-5

4. Huang KP, Acosta AA, Ghidewon MY, et al. Dissociable hindbrain GLP1R circuits for satiety and aversion. *Nature*. Jul 10 2024;doi:10.1038/s41586-024-07685-6

5. Burmeister MA, Ayala JE, Smouse H, et al. The Hypothalamic Glucagon-Like Peptide 1 Receptor Is Sufficient but Not Necessary for the Regulation of Energy Balance and Glucose Homeostasis in Mice. *Diabetes*. Feb 2017;66(2):372-384. doi:10.2337/db16-1102

6. Krieger JP, Arnold M, Pettersen KG, Lossel P, Langhans W, Lee SJ. Knockdown of GLP-1 Receptors in Vagal Afferents Affects Normal Food Intake and Glycemia. *Diabetes*. Jan 2016;65(1):34-43. doi:10.2337/db15-0973

7. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.

Lancet (London, England). Apr 16 2011;377(9774):1341-52. doi:10.1016/s0140-

6736(11)60205-5

8.   Topol EJ, Bousser MG, Fox KA, et al. Rimonabant for prevention of cardiovascular

events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. *Lancet (London,*

England). Aug 14 2010;376(9740):517-23. doi:10.1016/s0140-6736(10)60935-x

9.   Pi-Sunyer X, Apovian CM, McElroy SL, Dunayevich E, Acevedo LM, Greenway FL.

Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion

combination therapy: a pooled analysis. *International journal of obesity (2005)*. Oct

2019;43(10):2085-2094. doi:10.1038/s41366-018-0302-z

10.   Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and

placebo for smoking cessation. *The New England journal of medicine*. Oct 23

1997;337(17):1195-202. doi:10.1056/nejm199710233371703

11.   Mooney ME, Schmitz JM, Allen S, et al. Bupropion and naltrexone for smoking

cessation: A double-blind randomized placebo-controlled clinical trial. *Clinical pharmacology*

and therapeutics. Oct 2016;100(4):344-52. doi:10.1002/cpt.402

12.   Trivedi MH, Walker R, Ling W, et al. Bupropion and Naltrexone in Methamphetamine

Use Disorder. *The New England journal of medicine*. Jan 14 2021;384(2):140-153.

doi:10.1056/NEJMoa2020214

13.   European Medicines Agency. EMA statement on ongoing review of GLP-1 receptor

agonists. Accessed September 20, 2024. https://www.ema.europa.eu/en/news/ema-statement-

ongoing-review-glp-1-receptor-agonists

14. European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk

Assessment Committee (PRAC) 8-11 April 2024. Accessed September 20, 2024.

https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-

committee-prac-8-11-april-2024

15. US Food and Drug Administration. Update on FDA's ongoing evaluation of reports of

suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2

diabetes and obesity. Accessed September 20, 2024. https://www.fda.gov/drugs/drug-safety-

and-availability/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-

taking-certain-type

16. Wadden TA, Brown GK, Egebjerg C, et al. Psychiatric Safety of Semaglutide for Weight

Management in People Without Known Major Psychopathology: Post Hoc Analysis of the

STEP 1, 2, 3, and 5 Trials. *JAMA internal medicine*. Sep 3

2024;doi:10.1001/jamainternmed.2024.4346

17. Chen X, Zhao P, Wang W, Guo L, Pan Q. The Antidepressant Effects of GLP-1 Receptor

Agonists: A Systematic Review and Meta-Analysis. *The American journal of geriatric*

psychiatry : official journal of the American Association for Geriatric Psychiatry. Jan

2024;32(1):117-127. doi:10.1016/j.jagp.2023.08.010

18. Suchankova P, Yan J, Schwandt ML, et al. The glucagon-like peptide-1 receptor as a

potential treatment target in alcohol use disorder: evidence from human genetic association

studies and a mouse model of alcohol dependence. *Translational psychiatry*. Jun 16

2015;5(6):e583. doi:10.1038/tp.2015.68

19.   Aranäs C, Edvardsson CE, Shevchouk OT, et al. Semaglutide reduces alcohol intake and

relapse-like drinking in male and female rats. *EBioMedicine*. Jul 2023;93:104642.

doi:10.1016/j.ebiom.2023.104642

20.   Wium-Andersen IK, Wium-Andersen MK, Fink-Jensen A, Rungby J, Jørgensen MB,

Osler M. Use of GLP-1 receptor agonists and subsequent risk of alcohol-related events. A

nationwide register-based cohort and self-controlled case series study. *Basic & clinical*

pharmacology & toxicology. Nov 2022;131(5):372-379. doi:10.1111/bcpt.13776

21.   Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Associations of

semaglutide with incidence and recurrence of alcohol use disorder in real-world population.

Nature communications. May 28 2024;15(1):4548. doi:10.1038/s41467-024-48780-6

22.   Reitz J, Rosoff DB, Perlstein T, et al. Genetically modeled GLP1R and GIPR agonism

reduce binge drinking and alcohol-associated phenotypes: a multi-ancestry drug-target

Mendelian randomization study. *Mol Psychiatry*. Sep 10 2025;doi:10.1038/s41380-025-

03199-3

23.   Klausen MK, Jensen ME, Møller M, et al. Exenatide once weekly for alcohol use

disorder investigated in a randomized, placebo-controlled clinical trial. *JCI insight*. Oct 10

2022;7(19)doi:10.1172/jci.insight.159863

24.   Hendershot CS, Bremmer MP, Paladino MB, et al. Once-Weekly Semaglutide in Adults

With Alcohol Use Disorder: A Randomized Clinical Trial. *JAMA Psychiatry*. Apr 1

2025;82(4):395-405. doi:10.1001/jamapsychiatry.2024.4789

25.   Ganeshalingam AA, Uhrenholt NG, Arnfred S, Gæde PH, Bilenberg N, Frystyk J. Home-

based Intervention with Semaglutide Treatment of Neuroleptic-Related Prediabetes

(HISTORI): protocol describing a prospective, randomised, placebo controlled and double-

blinded multicentre trial. *BMJ open*. Mar 18 2024;14(3):e077173. doi:10.1136/bmjopen-2023-

077173

26. Köhne S, Hillemacher T, Glahn A, Bach P. Emerging drugs in phase II and III clinical

development for the treatment of alcohol use disorder. *Expert opinion on emerging drugs*. Sep

2024;29(3):219-232. doi:10.1080/14728214.2024.2342951

27. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian

randomization: using genes as instruments for making causal inferences in epidemiology.

Statistics in medicine. Apr 15 2008;27(8):1133-63. doi:10.1002/sim.3034

28. Zhao SS, Burgess S, Gill D. Glucagon-Like Peptide-1 Receptor Agonism and Suicide

Risk: Evidence From Mendelian Randomization. *Journal of the American Heart Association*.

Jun 18 2024;13(12):e035948. doi:10.1161/jaha.124.035948

29. Nguyen A, Smith E, Hashemy H, et al. Glucagon-like-peptide 1 receptor agonism and

attempted suicide: A Mendelian randomisation study to assess a potential causal association.

Clinical obesity. Aug 2024;14(4):e12676. doi:10.1111/cob.12676

30. Didelez V, Sheehan N. Mendelian randomization as an instrumental variable approach to

causal inference. *Statistical methods in medical research*. Aug 2007;16(4):309-30.

doi:10.1177/0962280206077743

31. Giambartolomei C, Vukcevic D, Schadt EE, et al. Bayesian test for colocalisation

between pairs of genetic association studies using summary statistics. *PLoS genetics*. May

2014;10(5):e1004383. doi:10.1371/journal.pgen.1004383

32. Kuehner C. Why is depression more common among women than among men? *The*

lancet Psychiatry. Feb 2017;4(2):146-158. doi:10.1016/s2215-0366(16)30263-2

33. Bölte S, Neufeld J, Marschik PB, Williams ZJ, Gallagher L, Lai MC. Sex and gender in

neurodevelopmental conditions. *Nature reviews Neurology*. Mar 2023;19(3):136-159.

doi:10.1038/s41582-023-00774-6

34. Gill D, Dib MJ, Cronjé HT, et al. Common pitfalls in drug target Mendelian

randomization and how to avoid them. *BMC Med*. Oct 15 2024;22(1):473.

doi:10.1186/s12916-024-03700-9

35. Locke AE, Kahali B, Berndt SI, et al. Genetic studies of body mass index yield new

insights for obesity biology. *Nature*. Feb 12 2015;518(7538):197-206.

doi:10.1038/nature14177

36. UK Biobank (Neale lab). http://www.nealelab.is/uk-biobank/.

37. Patel A, Gill D, Shungin D, et al. Robust use of phenotypic heterogeneity at drug target

genes for mechanistic insights: Application of cis-multivariable Mendelian randomization to

GLP1R gene region. *Genetic epidemiology*. Jun 2024;48(4):151-163. doi:10.1002/gepi.22551

38. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. *Gastroenterology*. May

2007;132(6):2131-57. doi:10.1053/j.gastro.2007.03.054

39. The GTEx Consortium atlas of genetic regulatory effects across human tissues. *Science*.

Sep 11 2020;369(6509):1318-1330. doi:10.1126/science.aaz1776

40. Aragam KG, Jiang T, Goel A, et al. Discovery and systematic characterization of risk

variants and genes for coronary artery disease in over a million participants. *Nat Genet*. Dec

2022;54(12):1803-1815. doi:10.1038/s41588-022-01233-6

41. Timmers PR, Mounier N, Lall K, et al. Genomics of 1 million parent lifespans implicates

novel pathways and common diseases and distinguishes survival chances. *eLife*. Jan 15

2019;8doi:10.7554/eLife.39856

42. Baselmans BML, Jansen R, Ip HF, et al. Multivariate genome-wide analyses of the well-

being spectrum. *Nature genetics*. Mar 2019;51(3):445-451. doi:10.1038/s41588-018-0320-8

43. Howard DM, Adams MJ, Clarke TK, et al. Genome-wide meta-analysis of depression

identifies 102 independent variants and highlights the importance of the prefrontal brain

regions. *Nature neuroscience*. Mar 2019;22(3):343-352. doi:10.1038/s41593-018-0326-7

44. Guintivano J, Byrne EM, Kiewa J, et al. Meta-Analyses of Genome-Wide Association

Studies for Postpartum Depression. *The American journal of psychiatry*. Dec 1

2023;180(12):884-895. doi:10.1176/appi.ajp.20230053

45. Mullins N, Forstner AJ, O'Connell KS, et al. Genome-wide association study of more

than 40,000 bipolar disorder cases provides new insights into the underlying biology. *Nature*

genetics. Jun 2021;53(6):817-829. doi:10.1038/s41588-021-00857-4

46. Nievergelt CM, Maihofer AX, Klengel T, et al. International meta-analysis of PTSD

genome-wide association studies identifies sex- and ancestry-specific genetic risk loci. *Nature*

communications. Oct 8 2019;10(1):4558. doi:10.1038/s41467-019-12576-w

47. Trubetskoy V, Pardiñas AF, Qi T, et al. Mapping genomic loci implicates genes and

synaptic biology in schizophrenia. *Nature*. Apr 2022;604(7906):502-508.

doi:10.1038/s41586-022-04434-5

48. Watson HJ, Yilmaz Z, Thornton LM, et al. Genome-wide association study identifies

eight risk loci and implicates metabo-psychiatric origins for anorexia nervosa. *Nature*

genetics. Aug 2019;51(8):1207-1214. doi:10.1038/s41588-019-0439-2

49. Demontis D, Walters GB, Athanasiadis G, et al. Genome-wide analyses of ADHD

identify 27 risk loci, refine the genetic architecture and implicate several cognitive domains.

Nature genetics. Feb 2023;55(2):198-208. doi:10.1038/s41588-022-01285-8

50. Martin J, Walters RK, Demontis D, et al. A Genetic Investigation of Sex Bias in the

Prevalence of Attention-Deficit/Hyperactivity Disorder. *Biological psychiatry*. Jun 15

2018;83(12):1044-1053. doi:10.1016/j.biopsych.2017.11.026

51. Grove J, Ripke S, Als TD, et al. Identification of common genetic risk variants for autism

spectrum disorder. *Nature genetics*. Mar 2019;51(3):431-444. doi:10.1038/s41588-019-0344-

8

52. Yu D, Sul JH, Tsetsos F, et al. Interrogating the Genetic Determinants of Tourette's

Syndrome and Other Tic Disorders Through Genome-Wide Association Studies. *The*

American journal of psychiatry. Mar 1 2019;176(3):217-227.

doi:10.1176/appi.ajp.2018.18070857

53. Hatoum AS, Colbert SMC, Johnson EC, et al. Multivariate genome-wide association

meta-analysis of over 1 million subjects identifies loci underlying multiple substance use

disorders. *Nature Mental health*. Mar 2023;1(3):210-223. doi:10.1038/s44220-023-00034-y

54. Johnson EC, Demontis D, Thorgeirsson TE, et al. A large-scale genome-wide association

study meta-analysis of cannabis use disorder. *The lancet Psychiatry*. Dec 2020;7(12):1032-

1045. doi:10.1016/s2215-0366(20)30339-4

55.   Walters RK, Polimanti R, Johnson EC, et al. Transancestral GWAS of alcohol

dependence reveals common genetic underpinnings with psychiatric disorders. *Nature*

neuroscience. Dec 2018;21(12):1656-1669. doi:10.1038/s41593-018-0275-1

56.   Sanchez-Roige S, Palmer AA, Fontanillas P, et al. Genome-Wide Association Study

Meta-Analysis of the Alcohol Use Disorders Identification Test (AUDIT) in Two Population-

Based Cohorts. *The American journal of psychiatry*. Feb 1 2019;176(2):107-118.

doi:10.1176/appi.ajp.2018.18040369

57.   Kurki MI, Karjalainen J, Palta P, et al. FinnGen provides genetic insights from a well-

phenotyped isolated population. *Nature*. Jan 2023;613(7944):508-518. doi:10.1038/s41586-

022-05473-8

58.   Lloyd-Jones LR, Robinson MR, Yang J, Visscher PM. Transformation of Summary

Statistics from Linear Mixed Model Association on All-or-None Traits to Odds Ratio.

Genetics. Apr 2018;208(4):1397-1408. doi:10.1534/genetics.117.300360

59.   Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan NA, Thompson JR.

Assessing the suitability of summary data for two-sample Mendelian randomization analyses

using MR-Egger regression: the role of the I2 statistic. *Int J Epidemiol*. Dec 1

2016;45(6):1961-1974. doi:10.1093/ije/dyw220

60.   Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with

multiple genetic variants using summarized data. *Genet Epidemiol*. Nov 2013;37(7):658-65.

doi:10.1002/gepi.21758

61. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian

Randomization with Some Invalid Instruments Using a Weighted Median Estimator. *Genetic*

epidemiology. May 2016;40(4):304-14. doi:10.1002/gepi.21965

62. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid

instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol*.

Apr 2015;44(2):512-25. doi:10.1093/ije/dyv080

63. Qingyuan Z, Jingshu W, Gibran H, Jack B, Dylan SS. Statistical inference in two-sample

summary-data Mendelian randomization using robust adjusted profile score. *The Annals of*

Statistics. 6/1 2020;48(3):1742-1769. doi:10.1214/19-AOS1866

64. Greco MF, Minelli C, Sheehan NA, Thompson JR. Detecting pleiotropy in Mendelian

randomisation studies with summary data and a continuous outcome. *Stat Med*. Sep 20

2015;34(21):2926-40. doi:10.1002/sim.6522

65. Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between

imprecisely measured traits using GWAS summary data. *PLoS genetics*. Nov

2017;13(11):e1007081. doi:10.1371/journal.pgen.1007081

66. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. *BMJ*

(Clinical research ed). Jan 25 2003;326(7382):219. doi:10.1136/bmj.326.7382.219

67. Zuber V, Grinberg NF, Gill D, et al. Combining evidence from Mendelian randomization

and colocalization: Review and comparison of approaches. *American journal of human*

genetics. May 5 2022;109(5):767-782. doi:10.1016/j.ajhg.2022.04.001

68. Foley CN, Staley JR, Breen PG, et al. A fast and efficient colocalization algorithm for

identifying shared genetic risk factors across multiple traits. *Nat Commun*. Feb 3

2021;12(1):764. doi:10.1038/s41467-020-20885-8

69. Mansur RB, Ahmed J, Cha DS, et al. Liraglutide promotes improvements in objective

measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label

study. *Journal of affective disorders*. Jan 1 2017;207:114-120. doi:10.1016/j.jad.2016.09.056

70. Mansur RB, Zugman A, Ahmed J, et al. Treatment with a GLP-1R agonist over four

weeks promotes weight loss-moderated changes in frontal-striatal brain structures in

individuals with mood disorders. *European neuropsychopharmacology : the journal of the*

European College of Neuropsychopharmacology. Nov 2017;27(11):1153-1162.

doi:10.1016/j.euroneuro.2017.08.433

71. Hammoud R, Drucker DJ. Beyond the pancreas: contrasting cardiometabolic actions of

GIP and GLP1. *Nature reviews Endocrinology*. Apr 2023;19(4):201-216. doi:10.1038/s41574-

022-00783-3

72. Meissner WG, Remy P, Giordana C, et al. Trial of Lixisenatide in Early Parkinson's

Disease. *The New England journal of medicine*. Apr 4 2024;390(13):1176-1185.

doi:10.1056/NEJMoa2312323

73. McGarry A, Rosanbalm S, Leinonen M, et al. Safety, tolerability, and efficacy of NLY01

in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial.

The Lancet Neurology. Jan 2024;23(1):37-45. doi:10.1016/s1474-4422(23)00378-2

74. Keller J, Gomez R, Williams G, et al. HPA axis in major depression: cortisol, clinical

712 symptomatology and genetic variation predict cognition. *Molecular psychiatry*. Apr

713 2017;22(4):527-536. doi:10.1038/mp.2016.120

714 75. Belvederi Murri M, Prestia D, Mondelli V, et al. The HPA axis in bipolar disorder:

715 Systematic review and meta-analysis. *Psychoneuroendocrinology*. Jan 2016;63:327-42.

716 doi:10.1016/j.psyneuen.2015.10.014

717 76. Cukierman-Yaffe T, Gerstein HC, Colhoun HM, et al. Effect of dulaglutide on cognitive

718 impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. *The Lancet*

719 *Neurology*. Jul 2020;19(7):582-590. doi:10.1016/s1474-4422(20)30173-3

720 77. Zhou L, Qu H, Yang L, Shou L. Effects of GLP1RAs on pregnancy rate and menstrual

721 cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review.

722 *BMC endocrine disorders*. Nov 8 2023;23(1):245. doi:10.1186/s12902-023-01500-5

723 78. Martel MM. Sexual selection and sex differences in the prevalence of childhood

724 externalizing and adolescent internalizing disorders. *Psychological bulletin*. Nov

725 2013;139(6):1221-59. doi:10.1037/a0032247

726 79. Yugar LBT, Sedenho-Prado LG, da Silva Ferreira IMC, Silva CAM, Sposito AC, Cercato

727 C. The efficacy and safety of GLP-1 receptor agonists in youth with type 2 diabetes: a meta-

728 analysis. *Diabetology & metabolic syndrome*. Apr 24 2024;16(1):92. doi:10.1186/s13098-

729 024-01337-5

730 80. MacDonald PE, El-Kholy W, Riedel MJ, Salapatek AM, Light PE, Wheeler MB. The

731 multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. *Diabetes*.

732 Dec 2002;51 Suppl 3:S434-42. doi:10.2337/diabetes.51.2007.s434

81. Adams DM, Reay WR, Geaghan MP, Cairns MJ. Investigation of glycaemic traits in

psychiatric disorders using Mendelian randomisation revealed a causal relationship with

anorexia nervosa. *Neuropsychopharmacology : official publication of the American College*

of Neuropsychopharmacology. May 2021;46(6):1093-1102. doi:10.1038/s41386-020-00847-

w

82. Shi Q, Nong K, Vandvik PO, et al. Benefits and harms of drug treatment for type 2

diabetes: systematic review and network meta-analysis of randomised controlled trials. *BMJ*

(Clinical research ed). Apr 6 2023;381:e074068. doi:10.1136/bmj-2022-074068

83. Ye CJ, Liu D, Chen ML, et al. Mendelian randomization evidence for the causal effect of

mental well-being on healthy aging. *Nature human behaviour*. Jun 17

2024;doi:10.1038/s41562-024-01905-9

84. Hou J, Manaenko A, Hakon J, Hansen-Schwartz J, Tang J, Zhang JH. Liraglutide, a long-

acting GLP-1 mimetic, and its metabolite attenuate inflammation after intracerebral

hemorrhage. *Journal of cerebral blood flow and metabolism : official journal of the*

International Society of Cerebral Blood Flow and Metabolism. Dec 2012;32(12):2201-10.

doi:10.1038/jcbfm.2012.133

85. Schooling CM, Yang G, Soliman GA, Leung GM. A Hypothesis That Glucagon-like

Peptide-1 Receptor Agonists Exert Immediate and Multifaceted Effects by Activating

Adenosine Monophosphate-Activate Protein Kinase (AMPK). *Life (Basel)*. Feb 7

2025;15(2)doi:10.3390/life15020253

86. Steinberg GR, Carling D. AMP-activated protein kinase: the current landscape for drug

development. *Nature reviews Drug discovery*. Jul 2019;18(7):527-551. doi:10.1038/s41573-

019-0019-2

87.   Minelli C, Del Greco MF, van der Plaat DA, Bowden J, Sheehan NA, Thompson J. The

use of two-sample methods for Mendelian randomization analyses on single large datasets.

International journal of epidemiology. Apr 26 2021;doi:10.1093/ije/dyab084

(a) BMI lowering

■ Lower BMI by GLP-1R activation   ⊖ Lower BMI

(b) HbA1c lowering

■ Lower HbA1c by GLP-1R activation   ⊖ Lower HbA1c

Outcome	Sample size	Beta (95% CI)	P value	Beta (95% CI)	P value
Well-being spectrum	2,370,390	0.06 (0.03 to 0.08)	<.001	0.003 (-0.02 to 0.02)	.81
		0.003 (0.00 to 0.01)	.04	-0.001 (-0.00 to 0.00)	.35
Life satisfaction	80,852	0.08 (0.04 to 0.12)	<.001	0.002 (-0.03 to 0.03)	.90
		0.003 (-0.00 to 0.01)	.05	-0.001 (-0.00 to 0.00)	.42
Positive affect	410,603	0.07 (0.04 to 0.10)	<.001	0.002 (-0.02 to 0.03)	.88
		0.002 (-0.00 to 0.01)	.16	-0.001 (-0.00 to 0.00)	.38
Neuroticism	582,989	-0.09 (-0.13 to -0.05)	<.001	-0.003 (-0.04 to 0.03)	.88
		-0.004 (-0.01 to 0.00)	.05	0.001 (-0.00 to 0.00)	.54
Depressive symptoms	1,295,946	-0.06 (-0.09 to -0.03)	<.001	-0.001 (-0.02 to 0.02)	.90
		-0.004 (-0.01 to -0.00)	.002	0.000 (-0.00 to 0.00)	.63

(a) axis: -0.15 -0.05 0.05 0.15

(b) axis: -0.05 0 0.05

Figure 1. IVW MR estimates for the associations of GLP-1R activation with mental health well-being.

BMI, body mass index; GLP-1R, glucagon-like peptide-1 receptor; HbA1c, glycated hemoglobin; IVW, inverse variance weighted; MR, Mendelian randomization. Black squares denote genetically predicted (a) lower BMI or (b) lower HbA1c via GLP-1R activation based on *GLP1R* variants. White circles denote genetically predicted (a) lower BMI or (b) lower HbA1c based on genome-wide variants. Positive associations with the well-being spectrum, life satisfaction, and positive affect and negative associations with neuroticism and depressive symptoms indicate better mental health well-being. Estimates are presented in standard deviation units for mental health well-being per 1-kg/m^2 decrease in BMI or per 1-mmol/mol decrease in HbA1c.

(a) BMI lowering

■ Lower BMI by GLP-1R activation   ⊖ Lower BMI

(b) HbA1c lowering

■ Lower HbA1c by GLP-1R activation   ⊖ Lower HbA1c

Outcome	Case/control	Odds ratio (95% CI)	P value	Odds ratio (95% CI)	P value
Depression	170,756/329,443	0.83 (0.74 to 0.94)	.003	1.03 (0.94 to 1.13)	.54
		0.98 (0.97 to 0.99)	<.001	1.00 (1.00 to 1.00)	.90
Post-partum depression	17,339/53,426	0.62 (0.43 to 0.89)	.01	0.83 (0.61 to 1.14)	.25
		0.98 (0.96 to 1.00)	.03	1.00 (0.99 to 1.01)	.41
Bipolar disorder	41,917/371,549	0.61 (0.47 to 0.79)	<.001	1.19 (0.97 to 1.46)	.09
		1.00 (0.98 to 1.02)	.77	1.01 (0.99 to 1.02)	.34
Bipolar disorder I	25,060/449,978	0.58 (0.42 to 0.80)	<.001	1.18 (0.92 to 1.53)	.20
		1.01 (0.98 to 1.03)	.57	1.01 (1.00 to 1.02)	.25
Bipolar disorder II	6,781/364,075	0.56 (0.32 to 0.97)	.04	1.47 (0.93 to 2.33)	.10
		1.00 (0.97 to 1.03)	.94	1.00 (0.99 to 1.02)	.86
PTSD	23,212/151,447	0.71 (0.47 to 1.07)	.10	1.24 (0.88 to 1.74)	.22
		0.94 (0.92 to 0.96)	<.001	1.00 (0.99 to 1.01)	.64
Schizophrenia	53,386/77,258	0.88 (0.69 to 1.11)	.28	1.13 (0.93 to 1.37)	.21
		1.03 (1.01 to 1.05)	.01	1.00 (0.99 to 1.01)	.45
Anorexia nervosa	16,992/55,525	0.95 (0.65 to 1.39)	.79	1.53 (1.13 to 2.09)	.007
		1.10 (1.07 to 1.12)	<.001	1.02 (1.00 to 1.03)	.02
ADHD	38,691/186,843	0.72 (0.55 to 0.94)	.01	0.89 (0.73 to 1.09)	.27
		0.89 (0.87 to 0.90)	<.001	0.99 (0.98 to 1.00)	.02
Autism spectrum disorder	18,381/27,969	0.69 (0.47 to 1.02)	.06	0.75 (0.55 to 1.03)	.07
		0.98 (0.95 to 1.00)	.05	1.00 (0.99 to 1.02)	.43
Tourette syndrome	4,819/9,488	1.27 (0.62 to 2.59)	.52	0.54 (0.31 to 0.94)	.03
		0.97 (0.93 to 1.01)	.14	0.99 (0.97 to 1.01)	.18

0.4 0.6 1.0 1.6 2.7   0.4 0.6 1.0 1.6 2.7

Figure 2. IVW MR estimates for the associations of GLP-1R activation with the risk of mental health disorders.

ADHD, attention deficit hyperactivity disorder; BMI, body mass index; GLP-1R, glucagon-like peptide-1 receptor; HbA1c, glycated

hemoglobin; IVW, inverse variance weighted; MR, Mendelian randomization; PTSD, post-traumatic stress disorder. Black squares denote

genetically predicted (a) lower BMI or (b) lower HbA1c via GLP-1R activation based on *GLP1R* variants. White circles denote genetically

predicted (a) lower BMI or (b) lower HbA1c based on genome-wide variants. Estimates are presented as odds ratio per 1-kg/m^2 decrease in BMI

or per 1-mmol/mol decrease in HbA1c.

(a) BMI lowering

■ Lower BMI by GLP-1R activation ⊖ Lower BMI

(b) HbA1c lowering

■ Lower HbA1c by GLP-1R activation ⊖ Lower HbA1c

Outcome	N (case/control)	Beta (95% CI)	P value	Beta (95% CI)	P value
Substance use disorders	1,025,550	-0.12 (-0.21 to -0.03)	.007	-0.004 (-0.05 to 0.05)	.87
		-0.01 (-0.02 to -0.01)	<.001	-0.001 (-0.00 to 0.00)	.49
Cannabis use disorder	14,080/343,726	-0.28 (-0.75 to 0.19)	.24	0.23 (-0.14 to 0.61)	.22
		-0.06 (-0.08 to -0.03)	<.001	-0.01 (-0.02 to 0.00)	.17
Alcohol dependence	8,485/20,272	-0.23 (-0.83 to 0.38)	.46	-0.27 (-0.78 to 0.24)	.30
		-0.01 (-0.05 to 0.02)	.35	0.002 (-0.02 to 0.02)	.86
AUDIT (total score)	121,604	-0.03 (-0.06 to 0.00)	.06	0.02 (-0.01 to 0.04)	.23
		0.003 (0.00 to 0.01)	.01	0.001 (0.00 to 0.00)	.02
AUDIT (alcohol consumption)	121,604	-0.02 (-0.05 to 0.01)	.17	0.02 (-0.01 to 0.04)	.13
		0.003 (0.00 to 0.01)	.001	0.001 (0.00 to 0.00)	.008
AUDIT (alcohol problems)	121,604	-0.03 (-0.06 to -0.00)	.04	0.01 (-0.01 to 0.03)	.35
		-0.001 (-0.00 to 0.00)	.16	0.000 (-0.00 to 0.00)	.78

Plot axes: -1   -0.5   0   0.5 (both panels)

Figure 3. IVW MR estimates for the associations of GLP-1R activation with the risk of substance use disorders and AUDIT scores.

AUDIT, Alcohol Use Disorders Identification Test; BMI, body mass index; GLP-1R, glucagon-like peptide-1 receptor; HbA1c, glycated hemoglobin; IVW, inverse variance weighted; MR, Mendelian randomization. Black squares denote genetically predicted (a) lower BMI or (b) lower HbA1c via GLP-1R activation based on *GLP1R* variants. White circles denote genetically predicted (a) lower BMI or (b) lower HbA1c based on genome-wide variants. Positive associations with AUDIT scores indicate higher risk of alcohol use disorders. Estimates are presented in

standard deviation unit for substance use disorder risk, as logodds for cannabis use disorder and alcohol dependence, and as log10 transformed

score for AUDIT scores per 1-kg/m^2 decrease in BMI or per 1-mmol/mol decrease in HbA1c.

Figure 4. Pairwise colocalization analyses for BMI and each significant outcome at the *GLP1R* gene.

BMI, body mass index. Probability for colocalization means the posterior probability of a shared variant associated with both traits; conditional

probability means the posterior probability of a shared variant associated with both traits conditional on the presence of a variant associated with

the outcome. Given the presence of a shared variant associated with both traits, the labeled variant had the largest probability of being the shared

causal variant.